Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Stage I/II Nasal NK Cell Lymphoma

21. Januar 2015 aktualisiert von: M.D. Anderson Cancer Center

Radiation Therapy Followed by Chemotherapy for Newly Diagnosed Patients With Stage I/II Nasal NK Cell Lymphoma

The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control stage 1 and/or 2 NK cell lymphoma. The safety of radiation and chemotherapy will also be studied.

Studienübersicht

Status

Beendet

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

The Study Treatments:

Radiation therapy is designed to kill cancer cells or to stop cancer cells from growing.

CHOP chemotherapy is made up of the drugs cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), and prednisone. It is designed to help control the tumor locally as well as the tumor cells that might have escaped and moved through the body.

Radiation Therapy:

You will receive radiation therapy 5 days a week for 28 to 30 treatments. You will receive a separate consent form that will describe this procedure and its risks in more detail.

Study Visits During Radiation Therapy:

Every week for 6 weeks during radiation therapy:

  • You will be asked how you are feeling and about any side effects you may be having.
  • Your performance status will be recorded.
  • You will have a physical exam.

Chemotherapy Administration:

The amount of time after you finish radiation therapy before you can begin receiving chemotherapy will depend on your recovery time and any side effects you may have. This should be about 3-4 weeks.

On Day 1 you will receive cyclophosphamide by vein over 1 hour, doxorubicin by vein over 15 minutes, and vincristine by vein over 15 minutes. You will take prednisone by mouth on Days 1-5 of each cycle. Each cycle will be 21-days long (or longer if it takes longer for your blood counts to recover). You will receive up to 4 cycles of chemotherapy.

Study Visits During Chemotherapy:

Before Day 1 of Cycle 1:

  • You will have a CT scan of head, neck, chest, abdomen and pelvis.
  • You will have an Magnetic resonance imaging (MRI) scan of the head and neck.
  • You will be asked about any drugs you may be taking and symptoms you may be having.
  • Your performance status will be recorded.
  • You will have a physical exam, including measurement of your height and weight.
  • You will have an echocardiogram (ECHO) and MUltiple Gated Acquisition scan (MUGA) scan.
  • You will have an x-ray of the chest.
  • You will have an Electrocardiography (ECG).
  • Blood (about 2 teaspoons) will be drawn for routine tests.
  • If you are able to become pregnant, you will have a blood (about 2 teaspoons) pregnancy test.

On Day 15 of Cycle 1:

  • You will be asked about any drugs you may be taking and symptoms you may be having.
  • Your performance status will be recorded.
  • Blood (about 2 teaspoons) will be drawn for routine tests.

On Day 1 of Cycles 2-4:

  • You will be asked about any drugs you may be taking and symptoms you may be having.
  • Your performance status will be recorded.
  • You will have an ECG.
  • Blood (about 2 teaspoons) will be drawn for routine tests.

On Day 15 of Cycles 2-4:

-Blood (about 2 teaspoons) will be drawn for routine tests.

Length of Study:

You may receive radiation and up to 4 cycles of CHOP. You will no longer be able to receive CHOP if the disease gets worse or intolerable side effects occur.

Your participation on the study will be over after the end-of-study and follow-up visits.

Follow-Up and End-of-Study Visits:

If you leave the study early:

  • You will have a computed tomography (CT) scan of head, neck, chest, abdomen and pelvis.
  • You will have an MRI scan of the head and neck.
  • You will have a positron emission tomography (PET)/CT scan.
  • Any skin lesions that you may have that are related to the tumor will be measured and photographed.
  • You will be asked about any drugs you may be taking and symptoms you may be having.
  • Your performance status will be recorded.
  • You will have a physical exam.
  • Blood (about 2 teaspoons) will be drawn for routine tests.

Routine Follow-up:

  • You will also have routine follow-up visits every 3 months for the 1st year, every 4 month during the 2nd year, and every 6 months during the 3rd-5th years. After that, you will have follow up visits 1 time every year. At these visits, the following tests and procedures will be recorded:
  • You will have a CT scan of head, neck, chest, abdomen and pelvis.
  • You will have an MRI scan of the head and neck.
  • You will have a PET/CT scan.
  • You will be asked about any symptoms you may be having.
  • Blood (about 2 teaspoons) will be drawn for routine tests.

Up to 40 patients will take part in this study. All will be enrolled at University of Texas (UT) MD Anderson Cancer Center.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

1

Phase

  • Phase 2
  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Vereinigte Staaten
    • Texas
      • Houston, Texas, Vereinigte Staaten, 77030
        • UT MD Anderson Cancer Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Patients with newly diagnosed stage I and II nasal Natural Killer (NK) cell lymphoma.
  2. Adequate blood cell counts (i.e. Absolute neutrophil count (ANC)> 1000) at baseline, or willingness to accept supportive measures such as transfusions, filgrastim, and Epoetin. Epoetin will not be administered concurrently with radiation.
  3. Patients must have adequate liver function as indicated by: *Bilirubin </= 1.5 times the upper limit of normal (ULN), * Alanine transaminase (ALT) </= 2 times the (ULN) or aspartate transaminase (AST) ≤ 2 times the ULN, *These values must be obtained within two weeks before protocol entry.
  4. Patients are required to have adequate renal function as indicated by a serum creatinine </= 2.5 mg/dL.This value must be obtained within two weeks before protocol entry.
  5. Left ventricular ejection fraction must be evaluated by nuclear medicine scan or echocardiography and measure >/= 50%.
  6. Male patients must agree to use a barrier method of contraception or agree to abstain from heterosexual activity for the duration of the study.
  7. Female patients must be willing to use two adequate barrier methods of contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study or be post menopausal (free from menses > two years or surgically sterilized).
  8. Female patients of childbearing potential must have a negative serum pregnancy test (BhCG) within 2 weeks of protocol entry.
  9. Patients must have the ability to give informed consent.

Exclusion Criteria:

  1. Patients with active Hepatitis B and/or Hepatitis C infection.
  2. Patients with active infections requiring specific anti-infective therapy are not eligible until all signs of infections are resolved.
  3. Patients known to be HIV positive.
  4. Patients with pre-existing cardiovascular disease requiring ongoing treatment. This includes: a) Congestive heart failure class III/IV (CHF) per new york heart association (NYHA) criteria. b) Cardiomyopathy, c) Uncontrolled cardiac arrhythmia, d) Unstable angina pectoris, e) Recent Myocardial infarction (MI) (within 6 months).
  5. Patients with prior exposure to anthracyclines:
  6. Patients who are pregnant or breast-feeding.
  7. Patients with psychiatric illness and/or social situations that would limit compliance with the study medication and requirements.
  8. Prior radiation to the site of current primary disease, if re-treatment would lead to violation of known radiation dose tolerance limits for that site.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Radiation + Chemotherapy
Radiation therapy total dose of 50.4 to 54 Gy over 28 to 30 treatments; CHOP Chemotherapy of Cyclophosphamide 750 mg/m2 intravenous piggyback (IVPB), Doxorubicin 50 mg/m2 IVPB, Vincristine 1.4 mg/m2 (max dose 2 mg) IVPB on Day 1, and Oral Prednisone 100 mg daily days 1-5 for four 21-day cycles.
Strahlung: Radiation
50.4 to 54 Gy delivered 5 days a week for 28 to 30 treatments.
Andere Namen:
  • Strahlentherapie
  • XRT
Arzneimittel: Cyclophosphamide
750 mg/m2 by vein over 1 hour on Day 1 of a 21 day cycle.
Andere Namen:
  • Cytoxan
  • Neosar
Arzneimittel: Doxorubicin
50 mg/m2 by vein over 15 minutes on Day 1 of a 21 day cycle.
Andere Namen:
  • Adriamycin
  • Rubex
Arzneimittel: Vincristine
1.4 mg/m2 (max dose 2 mg) by vein over 15 minutes on Day 1 of a 21 day cycle.
Andere Namen:
  • Oncovin
Arzneimittel: Prednisone
100 mg by mouth daily on Days 1-5 of a 21 day cycle.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Progression-free Survival (PFS)
Zeitfenster: Day 1 to disease progression or death (up to 5+ years)
Progression-free survival (PFS) defined as time from treatment initiation day to first documented progressive disease or death due to disease. Reviewed with each 21-day treatment cycle, followed every 3-4 months for first 2 years, annually thereafter.
Day 1 to disease progression or death (up to 5+ years)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

M.D. Anderson Cancer Center

Ermittler

  • Hauptermittler: Bouthaina Dabaja, MD, UT MD Anderson Cancer Center

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Nützliche Links

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Mai 2011

Primärer Abschluss (Tatsächlich)

1. Mai 2013

Studienabschluss (Tatsächlich)

1. Mai 2013

Studienanmeldedaten

Zuerst eingereicht

21. März 2011

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

21. März 2011

Zuerst gepostet (Schätzen)

23. März 2011

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

5. Februar 2015

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

21. Januar 2015

Zuletzt verifiziert

1. Mai 2014

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 2010-0035

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Lymphom

Klinische Studien zur Radiation

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Saudi Arabia

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

3
Abonnieren